Stem Cell Clinic

BHU prepares to be amongst top 500 global universities – Hindustan Times

By adminJune 3, 2020Stell Cell Research

With an aim to be a part of top 500 universities of the world, Banaras Hindu University (BHU) is expanding its international hostel, building smart classrooms, upgrading graduate and postgraduate laboratories, and beautifying its campus under the institute of excellence (IoE) scheme, said BHU public relations officer Dr Rajesh Singh.

Giving details of achievements of BHU in last one year, Dr Singh said that the government had sanctioned Rs 1000 crore under IoE scheme a few months ago to the university for upgrading infrastructure, academic and research facilities, laboratories, central and departmental libraries within five years.

Work has already started for upgrading academic and research facilities. The international hostel of 110 rooms is almost ready. It will help the university attract more foreign students.

He said with the financial support of the ministry of human resource development and union ministry of health and family welfare, a super speciality block worth Rs 200 crore has been built in BHU.

After being inaugurated by Prime Minister Narendra Modi, it is already functional. At present, it is providing medical services to Covid-19 patients. It is equipped with operation theatres, and biochemistry lab and pathology.

Moreover, bone marrow transplant and stem cell research centre have also been set up, construction of regional eye centre with an estimated cost of Rs 38.5 crore is about to be completed.

Singh said that with the financial support of union human resource development ministry, a central discovery centre, equipped with state of the art facilities, for research in basic and practical science is also being set up.

A SATHI centre with an estimated cost of Rs 125 crore is being set up in BHU. Under one roof, there will be facilities for innovation, entrepreneurship and development of startups.

He said that a centre for Vedic science has been set up in the university for research and to establish a link between ancient Indian knowledge and modern science. The centre will also work for reestablishing the excellent sources of knowledge, Vedas and its wide area and will also study their effect in understanding modern science and technology.

BHU has also signed an MoU with solar energy corporation for setting up a solar energy centre and a green energy centre for study in this field.

Dr Singh said that 369 research projects worth over Rs 157 crore are underway in the university.

More:
BHU prepares to be amongst top 500 global universities - Hindustan Times

Global Stem Cell Antibody Market Insights 2020 Demand Growing Rapidly with Major Player- Thermo Fisher Scientific, Merck Group, Abcam plc – Cole of…

By adminJune 3, 2020Stell Cell Research

Stem Cell Antibody Market Research Report released by Research N Reports is a tool to inform businesses on histories, current trends and ample research to navigate through its complexities. Effective business strategies of the leading key players and startups have been explained in detail. The Stem Cell Antibody Market is expected to reach at a huge CAGR during the forecast period.

The research report details the classification of the Stem Cell Antibody Market. The Stem Cell Antibody Market is divided into several segments based on materials, types, applications, and end-users. The report also includes a geographic analysis of the global market. The vital information mentioned in the research report will help to predict the future of the global market.

For Sample Copy of this report: https://www.researchnreports.com/request_sample.php?id=790931

The report delivers a comprehensive overview of the crucial elements of the Market and elements such as drivers, restraints, current trends of the past and present times, supervisory scenario, and technological growth. A thorough analysis of these elements has been accepted for defining the future growth prospects of the global Stem Cell Antibody Market.

Key Players:

Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.)

This statistical surveying research report on the Stem Cell Antibody is an all-inclusive study of the business sectors latest outlines, industry growth drivers, and inadequacies. It gives market forecasts for the coming years. It contains an examination of the latest progressions in technology, Porters five force analysis and dynamic profiles of exclusive industry competitors. The report besides conveys an investigation of trivial and full-scale factors prosecuting for the new candidates in the market and the ones currently in the market.

Ask for Discount on this Report: https://www.researchnreports.com/ask_for_discount.php?id=790931

Reasons for Buying this Report:

Across the globe, several regions like North America, Latin America, Asia-Pacific, Europe, and Africa have been studied on the basis of sale and profit margin. Some significant key players have been profiled to get informative data to make informed decisions in the businesses. It makes use of info graphics, graphs, charts, tables, and pictures. For an effective and accurate business outlook, the report on the global Stem Cell Antibody Market examined details of the changing trends adopted by the top level companies.

Get Complete [emailprotected] https://www.researchnreports.com/enquiry_before_buying.php?id=790931

About Us:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut throat Global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently we keep evolving as an all-rounder provider of viable information under one roof.

Contact:

Sunny Denis

Research N Reports

10916, Gold Point Dr,

Houston, TX, Pin 77064,

+1 510-402-1213,

[emailprotected]

https://www.researchnreports.com

Go here to read the rest:
Global Stem Cell Antibody Market Insights 2020 Demand Growing Rapidly with Major Player- Thermo Fisher Scientific, Merck Group, Abcam plc - Cole of...

Global Cell Isolation Technology Market 2020 SWOT Analysis & Key Business Strategies by Leading Industry Players and Forecast 2025 – 3rd Watch…

By adminJune 3, 2020Stell Cell Research

Recently MarketsandResearch.biz has published a new report entitled Global Cell Isolation Technology Market Growth (Status and Outlook) 2020-2025 goes into the past for analyzing the market scenario, at the same time, it provides a complete insight into the market. Starting from the number of sales made, the price structure of each segment, revenue generated and expected to be made, the margin of the profit, past performance, and all other aspects that can influence the market are covered in this report. The report has segmented and sub-segmented with respect to regions, players, dynamics, and strategies to simplify the actual conditions of the industry. It development trends, competitive landscape analysis, and key regions development status on the types, applications, and major players of the global Cell Isolation Technology market are studied in detail.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/59723

The Advancements Are Investigated Widely To Understand The Probable Impact On The Growth of The Global Market:

The Cell Isolation Technology market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The market report also includes statistics about sales, consumption rate, volume, value, gross margin, and more. The report also inspects the financial standing of the leading companies, which covers gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The segmentation included in the report is beneficial for companies to reach desired business goals. Business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions are some of the business events made by key players.

Leading manufacturers/companies operating at both regional and global levels: Thermo Fisher Scientific, Inc., Merck, Beckman Coulter, Inc., Terumo BCT, BD Biosciences, Bio-Rad Laboratories, Inc., GE Healthcare, Stemcell Technologies,

With the product, the market could be divided into: Centrifugation, Flow Cytometry, Cell Electrophoresis,

With users/application, the market can be split into: Stem cell research, Cancer research, Tissue regeneration, In-vitro diagnostics, Other

By Leading Regions:

Analysts have created this report by gathering information through primary through surveys and interviews and secondary included industry body databases, reputable paid sources, and trade journal methods of data collection. The report includes exhaustive qualitative and quantitative evaluation. Analysts have taken meticulous efforts to take a look at the right and valuable statistics and serve this intelligence document.

This includes key regional areas such as Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/59723/global-cell-isolation-technology-market-growth-status-and-outlook-2020-2025

Why Should One Grab This Industry Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Autologous Stem Cell Transplantation Market: COVID 19 Effect Will Take a Revenue Generation System in a New Level: ANTRIA (CRO), BIOHEART, BRAINSTORM…

By adminJune 3, 2020Stell Cell Research

(Jan 2020) WMR has released a report on Autologous Stem Cell Transplantation Market 2027. It provides key insights through details and gives customers a competitive advantage. Autologous Stem Cell Transplantation Industry Size, Market Share Value, Competitor Surveys, Industry Outlook and Analytics cover a variety of factors such as geographic analysis, Autologous Stem Cell Transplantation types, applications, and more.

Worldwide Market Reports Autologous Stem Cell Transplantation Industry information includes surveys based on Current Scenarios, Historical Records and Future Forecasts. Organize accurate data from various aspects. It provides a 360 overview of the industrys competitive environment. This helps companies understand threats and challenges in front of their business.

Download PDF Brochure with Full Analysis of Key Players: https://www.worldwidemarketreports.com/sample/285423

NOTE: This report Sample includes: Brief Introduction to the research report, Table of Contents (Scope covered as a part of the study), Top players in the market, Research framework (Structure of the actual report), The research methodology adopted by Worldwide Market Reports

Following Key Players are Analysed in this Report: ANTRIA (CRO), BIOHEART, BRAINSTORM CELL THERAPEUTICS, CYTORI, DENDREON CORPORATION, FIBROCELL, GENESIS BIOPHARMA, GEORGIA HEALTH SCIENCES UNIVERSITY, NEOSTEM, OPEXA THERAPEUTICS, ORGENESIS, REGENEXX, REGENEUS, TENGION, TIGENIX, VIRXSYS

(*other Player can be added on demand)

Regional Insights of Autologous Stem Cell Transplantation Market

Autologous Stem Cell Transplantation Report Covers:

In the end, the Autologous Stem Cell Transplantation Market Report provides an insight and expert analysis of the markets key trends and behaviors along with an overview of market data and key brands. Autologous Stem Cell Transplantation Market Reports provide all data with easily digestible information to drive future innovation and advance your business for every entrepreneur as well as for established Enterprises.

Customization Service of the Report: https://www.worldwidemarketreports.com/quiry/285423

Worldwide Market Reports provides customized upon request. This report can be personalized to suit your needs. Please contact the research team to ensure you receive the report that fits your needs.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Read the original:
Autologous Stem Cell Transplantation Market: COVID 19 Effect Will Take a Revenue Generation System in a New Level: ANTRIA (CRO), BIOHEART, BRAINSTORM...

Potential Impact of Covid-19 Outbreak On Stem Cell Assay Market Business Outlook, Analysis and Forecast 2020 2027 to 2027 | Merck & Co., Thermo…

By adminJune 3, 2020Stell Cell Research

CMI announced that its published an exclusive report namely Global Stem Cell Assay Market by Manufacturers, Regions, Type and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Stem Cell Assay Market. This is an informative study covering the market with in-depth analysis and portraying the current state of affairs in the industry.

Read Summary Of Stem Cell Assay Market Report @ https://www.coherentmarketinsights.com/ongoing-insight/stem-cell-assay-market-1632

The report presents an overview of Stem Cell Assay Market consist of objectives study and definition of Stem Cell Assay. The next section focuses on market size, region-wise Stem Cell Assay production value ($) and growth rate estimation from 2020-2027. Manufacturers are taking innovative strategies to increase the market share of their products. The success of new product launches is expected to speedup players for business growth.

This Report Covers Leading Companies Associated in Worldwide Stem Cell Assay Market: Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

We do provide Sample of this report, Please go through the following information in order to request Sample Copy

This Report Sample Includes

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Get Sample Copy Of This Report @https://www.coherentmarketinsights.com/insight/request-sample/1632

Stem Cell Assay Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Detailed Segmentation of Stem Cell Assay Market:

By Product Type-InstrumentsReagents & KitsBy Cell Type Adult Stem CellsInduced Pluripotent Stem CellsMesenchymal Stem CellsNeural Stem CellsHematopoietic Stem CellsUmbilical Cord Stem CellsHuman Embryonic Stem CellsBy Process Cell CultureEngineeringDifferentiationCharacterizationOthersBy Application -ResearchDrug Discovery & DevelopmentRegenerative Medicine

Following market aspects are enfolded in Global Stem Cell Assay Market Report:

Stem Cell Assay Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Stem Cell Assay Market players in detail. Stem Cell Assay Market report gives key bits of Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Note: Request Discount option enables you to get the discounts on the actual price of the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss your allocated budget, and would provide discounts.

Ask Discount Before Purchasing @https://www.coherentmarketinsights.com/insight/request-discount/1632

Key questions answered in Report:-

Stem Cell Assay Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027

Consumption Analysis of Stem Cell Assay, Guidelines Overview and Upcoming Trends Forecast till 2027

Stem Cell Assay Market Top Companies Sales, Price, Revenue and Market Share Outlook

Stem Cell Assay Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027

Analytical Overview, Growth Factors, Demand and Trends

Stem Cell Assay by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027

Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast

Stem Cell Assay Overview, Raw Materials Analysis, Market Drivers and Opportunities

In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells – Yahoo Finance

By adminJune 3, 2020Stem Cell Medical Center

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, June 1, 2020 /PRNewswire/ --Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

For information please contact:

Paul Lehr, JDplehr@longeveron.com305-338-6257

Related Images

longeveron.png LONGEVERON Longeveron - Biological Solutions for Aging

Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research – WhaTech Technology and Markets News

By adminJune 3, 2020Stem Cell Medical Center

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

See the original post:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL – Targeted Oncology

By adminJune 3, 2020Stem Cell Treatment

Optimized tandem CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy induced potent and durable anti-tumor responses as treatment of patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL) with good control of cytokine release syndrome (CRS) and CAR T-related encephalopathy syndrome, according to a phase 1/2 clinical trial presented in a poster at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

After a median of 13.5 months of follow-up (IQR, 33.2-3.3), 84% of patients had an objective response, and 74% had a complete response (CR). The duration of overall response rate (ORR) at 6 months was 94% and 74% at 12 months.

Both the median progression-free and overall survivals had not been reached for patients at the time of data cut-off. At 6 months, the progression-free survival rate was 76%, and at 12 months, it was 59%.

Sixty-two patients experienced CRS (71%), which was grade 1 or 2 in 61% of patients and grade 3 or greater in 10%. The median time to the onset of CRS after infusion was 1 day (range, 1-5). The median duration of CRS was 6 days (range, 1-9). Investigators also noted that the median time to the onset of grade 3 CRS was 1 day (range, 1-2).

The most common adverse events within 1 month of the IV infusion were leukopenia, pyrexia, and anorexia. Only 2 patients (2%) experienced CAR T-cell-related encephalopathy syndrome of grade 3 severity.

Three treatment-related deaths occurred in the study, 2 due to pulmonary infection and 1 due to deposition of CAR T cells in pulmonary alveoli.

Ninety-nine patients were screened for the study, of which 87 received the infusion and 74 were followed for at least 3 months before the data cutoff date. Patients underwent leukapheresis and conditioning chemotherapy, which was followed by a single intravenous infusion of tandem CD19/20 CAR T cells on day 0 at a dose of 0.5x106x106 per kg of body weight.

The majority of patients in the study were under the age of 60 years (82%) and female (53%). Overall, 62% of patients had an ECOG performance status of 0 or 1 versus 38% who had a 2. Upon study entry, 85% had stage III or IV disease and 15% had stage I or II. Patients were diagnosed with either diffuse large B-cell lymphoma (66%), follicular lymphoma (15%), transformed follicular lymphoma (7%), primary mediastinal B-cell lymphoma (6%) or other (6%).

Fifty-six percent of patients had 3 to 5 prior lines of anti-neoplastic therapy, while 27% had 2 or less and 17% had 6 or more. The majority of patients had a lesion diameter less than 10 cm (78%) and had tumor burden SPD of 100 cm2 or more (55%). Eighty percent of the patients were refractory, 20% had relapsed to second-line or later therapy, 14% became refractory after stem cell transplant, and 10% had relapsed after a prior CD19 CAR-T cell therapy.

To be eligible for the study, patients had to be between the ages of 16 and 70 years, and they could not have received prior anti-CD20 monoclonal antibody and anthracycline treatment. Patients had to have an ECOG performance status of 0 to 2 with a life expectancy greater than 3 months and adequate organ function to enroll in the study. Patients also had to have measurable disease according to the IWG Response Criteria for Malignant Lymphoma.

Patients who had a CR with no evidence of disease were ineligible to enroll. If they had definite involvement of the gastrointestinal tract, negative tumor puncture detection in both CD19 and CD20, or had serious uncontrolled medical disorders or active infections, they also could not enroll. Patients were also excluded from the study if they were deemed unsuitable for the trial based on clinical judgement or were pregnant or lactating.

CD19-targeted CAR T cells have been highly effective in the treatment landscape of hematologic malignancies, but the recurrence rate appears high, which is a major obstacle to durable remissions with this therapy. This study aimed to evaluate the safety and tolerability of intravenous tandem CD19/20 CAR T cells among patients with relapsed/refractory NHL.

Secondary objectives of this study also included assessment of efficacy of the study treatment defined by ORR and evaluation of the duration of overall response, progression-free and overall survival. An exploratory objective of the study was to determine in vivo expansion and persistence of the Tandem CD19/CD20 CAR T cells.

The rationale for this study was to address the high recurrence rate observed with CAR T-cell therapy, which often prevents durable remission after treatment. Overall the optimized tandem CAR T treatment appeared feasible in patients with B-NHL. Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory ORR and CR rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.

Reference

Ja-Jing Z, Yao W, Zhi-Qiang Wu, et al. Safety and Efficacy of Optimized Tandem CD19/CD20 CAR-Engineered T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 38: 2020 (suppl; abstr 3034). doi: 10.1200/JCO.2020.38.15_suppl.3034

Go here to read the rest:
Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL - Targeted Oncology

ReNeuron encouraged by progress in stroke and RP treatments – Proactive Investors UK

By adminJune 3, 2020Stem Cell Treatment

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina.

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

CTX Cells

CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.

Reneurons product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that arebelieved to play a key role in cell-to-cell communication.

ExoPr0, Reneurons first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

hRPC

's ()human retinal progenitor cells (hRPC) have scored some early success.

A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

Six months after treatment there was a mean improvement of 18.5per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereasinexorable disease progression is the norm for this disease.

With a total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye threemonths after treatment.

In February, clinicaldata from the PISCES II clinical trial were published in peer-reviewedJournal of Neurology, Neurosurgery, and Psychiatry.

CTX

A peer journal review published in May indicated a CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

ReNeuron has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.

The new data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

Coronavirus

In April, Reneuron said it haddeveloped a line of the human exosomes that can deliver a medically relevant payload: Viral vaccines thatmight help in the fight against coronavirus.

The stem cell specialist added that the disruption from lockdowns would inevitably lead to delays in the recruitment of patients for trials of its treatments for stroke disability and retinitis pigmentosa (RP).

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

More:
ReNeuron encouraged by progress in stroke and RP treatments - Proactive Investors UK

NexImmune to Present at the Jefferies Virtual Healthcare Conference – GlobeNewswire

By adminJune 3, 2020Stem Cell Treatment

GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced thatJohn Trainer, Chief Financial Officer, will present a company overview at theJefferies Virtual Healthcare ConferenceonTuesday, June 2, 2020at3:30 p.m. Eastern time.

About NexImmunes Lead T Cell Therapy Programs

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Company expects initial data in the fourth quarter of 2020.The Companys pipeline also consists of four additional preclinical programs, including cell therapy and injectable product candidates for the treatment of oncology, autoimmune diseases, and infectious diseases.

About NexImmune

NexImmune is a Gaithersburg, MD-based clinical-stage biopharma company advancing a new generation of immunotherapies based on its proprietary artificial immune modulation (AIM) technology. The AIM platform is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nano-particles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties, including the ability to address key mechanisms of tumor escape and relapse through a unique combination of anti-tumor potency, multi-antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas (autoimmune diseases and infectious diseases), with both cell therapy and injectable products. For more information, visit http://www.neximmune.com.

Media Contact:Mike BeyerSam Brown Inc. Healthcare Communications312-961-2502mikebeyer@sambrown.com

View original post here:
NexImmune to Present at the Jefferies Virtual Healthcare Conference - GlobeNewswire